SFDA Approved 434 New Drugs In 2008
This article was originally published in PharmAsia News
Executive Summary
China's State FDA accepted a total of 3,413 applications for drug registrations in 2008. The total number decreased by 75 percent and 18 percent compared to the same period in 2006 and 2007, largely because of a sharp drop in the number of applications of imitation drugs and modified drugs. SFDA approved a total of 434 new drugs for clinical applications, of which 52 are new compounds. The agency approved a total of 165 applications for new drug production, of 119 different drugs; and it approved a total of 99 applications for importation of medicines, involving 83 drugs. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.